Modelling Human Granulopoiesis under Poly-chemotherapy with G-CSF Support

Abstract.Cytotoxic drugs administered in polychemotherapy cause a characteristic neutropenic period depending on the schedule of the drugs, which can partly be prevented by G-CSF growth factor support. To quantify these effects and to gain a deeper insight into the dynamics of bone marrow recovery after such suppressing and stimulating disturbances, we construct a biomathematical compartment model of human granulopoiesis under polychemotherapy with G-CSF support. The underlying assumptions and mathematical techniques used to obtain the model are explained in detail. A large variety of biological and clinical data as well as knowledge from a model of murine haematopoiesis are evaluated to construct a physiological model for humans.Particular emphasis is placed on estimating the influence of chemotherapeutic drugs on the granulopoietic system. As a result, we present an innovative method to estimate the bone marrow damage caused by cytotoxic drugs with respect to single identifiable cell stages only on the basis of measured peripheral blood leukocyte dynamics. Conversely, our model can be used in a planning phase of a clinical trial to estimate the haematotoxicity of regimens based on new combinations of drugs already considered and with or without growth factor support.

[1]  J. Sinkule.  Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent , 1984, Pharmacotherapy.

[2]  M. C. Mackey,et al.  The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans , 2003, Cell proliferation.

[3]  Ivar Østby,et al.  A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation , 2003, Journal of mathematical biology.

[4]  E. Ashihara,et al.  Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation. , 1995, Experimental hematology.

[5]  H E Wichmann,et al.  A mathematical model of erythropoiesis in mice and rats Part 1: Structure of the model , 1989, Cell and tissue kinetics.

[6]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. , 2004, Blood.

[7]  J. Borleffs,et al.  Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects. , 1998, Clinical therapeutics.

[8]  M. Eichelbaum,et al.  Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Priv.-Doz. Dr. Hans-Peter Lohrmann,et al.  Recent Results in Cancer Research , 2011 .

[10]  Markus Scholz,et al.  A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. , 2004, Blood.

[11]  H E Wichmann,et al.  Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis. , 1993, Experimental hematology.

[12]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. , 2004, Blood.

[13]  M Takahashi,et al.  Theoretical basis for cell cycle analysis: II. Further studies on labelled mitosis wave method. , 1968, Journal of theoretical biology.

[14]  A. Karim.  The pharmacokinetics of Norpace. , 1975, Angiology.

[15]  Hans-Paul Schwefel,et al.  Evolution strategies: A family of non-linear optimization techniques based on imitating some principles of organic evolution , 1984, Ann. Oper. Res..

[16]  G. Chatta,et al.  Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. , 1996, Blood.

[17]  A Howell,et al.  The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[19]  M. Pfreundschuh,et al.  Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Melenhorst,et al.  Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. , 2003, Blood.

[21]  L. Lewis,et al.  The role of polymorphonuclear neutrophils (PMNs) in clearance of granulocyte colony-stimulating factor (G-CSF) in vivo and in vitro. , 1997, Experimental Hematology.

[22]  H E Wichmann,et al.  Model analysis of the contrasting effects of GM‐CSF and G‐CSF treatment on peripheral blood neutrophils observed in three patients with childhood‐onset cyclic neutropenia , 1996, British journal of haematology.

[23]  R. Hoffman,et al.  Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. , 1996, Experimental hematology.

[24]  A. Mantovani,et al.  Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. , 1992, Blood.

[25]  Manabu Takahashi,et al.  Theoretical basis for cell cycle analysis I. Labelled mitosis wave method , 1966 .

[26]  A. Zelenetz,et al.  Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  L. Hareng,et al.  Induction and Regulation of Endogenous Granulocyte Colony-Stimulating Factor Formation , 2002, Biological chemistry.

[28]  V. Diehl,et al.  Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  H E Wichmann,et al.  Synchrony of bone marrow proliferation and maturation as the origin of cyclic haemopoiesis , 1990, Cell and tissue kinetics.

[30]  S. Lenhoff,et al.  Granulocyte interactions with GM-CSF and G-CSF secretion by endothelial cells and monocytes. , 1999, European cytokine network.

[31]  M M Wintrobe,et al.  Leukokinetic studies. 13. A non-steady-state kinetic evaluation of the mechanism of cortisone-induced granulocytosis. , 1968, The Journal of clinical investigation.

[32]  L. Druhan,et al.  Proteolytic cleavage of granulocyte colony‐stimulating factor and its receptor by neutrophil elastase induces growth inhibition and decreased cell surface expression of the granulocyte colony‐stimulating factor receptor , 2003, American journal of hematology.

[33]  T. Tötterman,et al.  Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. , 1996, Bone marrow transplantation.

[34]  A. Fauci,et al.  Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. , 1974, The New England journal of medicine.

[35]  L. Ferguson,et al.  The clinical use of mutagenic anticancer drugs. , 1996, Mutation research.

[36]  R. Fisher,et al.  Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Allen,et al.  Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. , 1994, Blood.

[38]  V. Oliverio,et al.  The pharmacokinetics of [3H]‐vincristine in man , 1977, Clinical pharmacology and therapeutics.